Therapeutics Targeting the Core Apoptotic Machinery

Claudia Hamilton, Jennifer P. Fox, Daniel B. Longley, Catherine A. Higgins*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

13 Citations (Scopus)
273 Downloads (Pure)


Therapeutic targeting of the apoptotic pathways for the treatment of cancer is emerging as a valid and exciting approach in anti-cancer therapeutics. Accumulating evidence demonstrates that cancer cells are typically “addicted” to a small number of anti-apoptotic proteins for their survival, and direct targeting of these proteins could provide valuable approaches for directly killing cancer cells. Several approaches and agents are in clinical development targeting either the intrinsic mitochondrial apoptotic pathway or the extrinsic death receptor mediated pathways. In this review, we discuss the main apoptosis pathways and the key molecular targets which are the subject of several drug development approaches, the clinical development of these agents and the emerging resistance factors and combinatorial treatment approaches for this class of agents with existing and emerging novel targeted anti-cancer therapeutics.
Original languageEnglish
Article number2618
Number of pages27
Issue number11
Publication statusPublished - 26 May 2021


  • apoptosis
  • cancer therapeutics
  • resistance
  • FLIP


Dive into the research topics of 'Therapeutics Targeting the Core Apoptotic Machinery'. Together they form a unique fingerprint.

Cite this